Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUTH-DKD Study of tofogliflozin versus metformin in diabetic kidney disease
jRCTs031210339Active, not recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tofogliflozin and metformin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in urine albumin-to-creatinine ratio. Started Nov 2021; status: active, not recruiting.
02
Drugs
tofogliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs031210339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210339.